Evidence map›Paper›PMID 28716012›Full record

ArticleBMC medical genetics2017

Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene.

Parvaneh Karimzadeh, Samaneh Naderi, Farzaneh Modarresi, Hassan Dastsooz, Hamid Nemati, Tayebeh Farokhashtiani, Bibi Shahin Shamsian, Soroor Inaloo, Mohammad Ali Faghihi

Registry-linked trialOpen access · goldAbstract readCase Reports
In one paragraph

Article in BMC medical genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02030015 (Synergistic Enteral Regimen for Treatment of the Gangliosidoses), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02030015 phase4terminatednot on this map

Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)

TypeinterventionalSponsorUniversity of MinnesotaRan2015 to 2019Enrolled16ConditionsGM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease, Sandhoff DiseaseArmsmiglustat, Ketogenic Diet
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. GM1 gangliosidosis type II: Results of a 10-year prospective study.Genetics in medicine : official journal of the American College of Medical Genetics · 2024
    Observational
  7. GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study.medRxiv : the preprint server for health sciences · 2024
    Article
  8. Article
  9. Rare Diseases in Glycosphingolipid Metabolism.Advances in experimental medicine and biology · 2022
    Article
  10. Article
  11. GM1 Gangliosidosis-A Mini-Review.Frontiers in genetics · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Parvaneh KarimzadehPediatric Neurology Department, Pediatric Neurology Research Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
Samaneh NaderiDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Farzaneh ModarresiCenter for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, USA.
Hassan DastsoozComprehensive Medical Genetic Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamid NematiShiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. nematih@sums.ac.ir.
Tayebeh FarokhashtianiPediatric Neurology Department, Pediatric Neurology Research Center, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
Bibi Shahin ShamsianPediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Soroor InalooNeonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Ali FaghihiCenter for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, USA. MFaghihi@med.miami.edu.ORCID 0000-0002-8330-9067
Shiraz University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRUniversity of Miami · US

Funding

Antisense RNA Mediated Epigenetic Regulation of Brain Derived Neurotrophic FactorR01NS081208 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FAGHIHI, MOHAMMAD ALI · 2013 to 2017
$1.7M
NINDS NIH HHS R01 NS081208
6 · The paper itself

Abstract

backgroundType II or juvenile GM1-gangliosidosis is an autosomal recessive lysosomal storage disorder, which is clinically distinct from infantile form of the disease by the lack of characteristic cherry-red spot and hepatosplenomegaly. The disease is characterized by slowly progressive neurodegeneration and mild skeletal changes. Due to the later age of onset and uncharacteristic presentation, diagnosis is frequently puzzled with other ataxic and purely neurological disorders. Up to now, 3-4 types of GM1-gangliosidosis have been reported and among them type I is the most common phenotype with the age of onset around 6 months. Various forms of GM1-gangliosidosis are caused by GLB1 gene mutations but severity of the disease and age of onset are directly related to the position and the nature of deleterious mutations. However, due to its unique genetic cause and overlapping clinical features, some researchers believe that GM1 gangliosidosis represents an overlapped disease spectrum instead of four distinct types. CASE PRESENTATION: Here, we report a less frequent type of autosomal recessive GM1 gangliosidosis with perplexing clinical presentation in three families in the southwest part of Iran, who are unrelated but all from "Lurs" ethnic background. To identify disease-causing mutations, Whole Exome Sequencing (WES) utilizing next generation sequencing was performed. Four patients from three families were investigated with the age of onset around 3 years old. Clinical presentations were ataxia, gate disturbances and dystonia leading to wheelchair-dependent disability, regression of intellectual abilities, and general developmental regression. They all were born in consanguineous families with no previous documented similar disease in their parents. A homozygote missense mutation in GLB1 gene (c. 601 G > A, p.R201C) was found in all patients. Using Sanger sequencing this identified mutation was confirmed in the proband, their parents, grandparents, and extended family members, confirming its autosomal recessive pattern of inheritance.

conclusionsOur study identified a rare pathogenic missense mutation in GLB1 gene in patients with complex neurodevelopmental findings, which can extend the list of differential diagnoses for childhood ataxia in Iranian patients.

Indexed as

Mutation, Missensebeta-GalactosidaseChildChild, PreschoolConsanguinityFemaleGangliosidosis, GM1HumansMalebeta-GalactosidaseGLB1 protein, humanCase reportGLB1GM1 gangliosidosis

Identifiers

PMID28716012
PMCPMC5513107
OpenAlexW2734495263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.